Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology.

Gliomas are uniformly fatal forms of primary brain neoplasms that vary from low- to high-grade (glioblastoma). Whereas low-grade gliomas are weakly angiogenic, glioblastomas are among the most angiogenic tumors. Thus, interactions between glioma cells and their tissue microenvironment may play an important role in aggressive tumor formation and progression. To quantitatively explore how tumor cells interact with their tissue microenvironment, we incorporated the interactions of normoxic glioma cells, hypoxic glioma cells, vascular endothelial cells, diffusible angiogenic factors, and necrosis formation into a first-generation, biologically based mathematical model for glioma growth and invasion. Model simulations quantitatively described the spectrum of in vivo dynamics of gliomas visualized with medical imaging. Furthermore, we investigated how proliferation and dispersal of glioma cells combine to induce increasing degrees of cellularity, mitoses, hypoxia-induced neoangiogenesis and necrosis, features that characterize increasing degrees of "malignancy," and we found that changes in the net rates of proliferation (ρ) and invasion (D) are not always necessary for malignant progression. Thus, although other factors, including the accumulation of genetic mutations, can change cellular phenotype (e.g., proliferation and invasion rates), this study suggests that these are not required for malignant progression. Simulated results are placed in the context of the current clinical World Health Organization grading scheme for studying specific patient examples. This study suggests that through the application of the proposed model for tumor-microenvironment interactions, predictable patterns of dynamic changes in glioma histology distinct from changes in cellular phenotype (e.g., proliferation and invasion rates) may be identified, thus providing a powerful clinical tool.

[1]  Paul E Kinahan,et al.  Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images. , 2011, Mathematical medicine and biology : a journal of the IMA.

[2]  K Hendrickson,et al.  Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.

[3]  T. Cloughesy,et al.  Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. , 2009, Cancer research.

[4]  David Basanta,et al.  The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. , 2009, Cancer research.

[5]  Gargi Chakraborty,et al.  Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. , 2009, Cancer research.

[6]  K. Swanson,et al.  Complementary but Distinct Roles for MRI and 18F-Fluoromisonidazole PET in the Assessment of Human Glioblastomas , 2008, Journal of Nuclear Medicine.

[7]  D. Gillespie,et al.  Hypoxia‐regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme , 2008, Cancer.

[8]  J M Wardlaw,et al.  Velocity of radial expansion of contrast-enhancing gliomas and the effectiveness of radiotherapy in individual patients: a proof of principle. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[9]  K. Swanson,et al.  A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle , 2007, British Journal of Cancer.

[10]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[11]  Kristin R. Swanson,et al.  The Evolution of Mathematical Modeling of Glioma Proliferation and Invasion , 2007, Journal of neuropathology and experimental neurology.

[12]  Y. Ueno,et al.  Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma. , 2006, Anticancer research.

[13]  Luc Taillandier,et al.  Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas , 2006, Annals of neurology.

[14]  A. Hilbig,et al.  Expression of nestin and vimentin in gliomatosis cerebri. , 2006, Arquivos de neuro-psiquiatria.

[15]  A. Unterberg,et al.  Different angiogenic phenotypes in primary and secondary glioblastomas , 2006, International journal of cancer.

[16]  S. Turner,et al.  Measurement of Endothelial Cell Proliferation Rate in vivo Using 2H2O Labeling: A Kinetics Biomaker of Angiogenesis , 2006 .

[17]  D. Zagzag,et al.  Angiogenesis in Gliomas: Biology and Molecular Pathophysiology , 2005, Brain pathology.

[18]  P. Korkolopoulou,et al.  Hypoxia‐inducible factor 1α/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis , 2004, Neuropathology and applied neurobiology.

[19]  J. Murray,et al.  Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion , 2003, Journal of the Neurological Sciences.

[20]  Kristin R. Swanson,et al.  Virtual resection of gliomas: Effect of extent of resection on recurrence , 2003 .

[21]  L. Preziosi,et al.  Modeling the early stages of vascular network assembly , 2003, The EMBO journal.

[22]  Laurent Capelle,et al.  Continuous growth of mean tumor diameter in a subset of grade II gliomas , 2003, Annals of neurology.

[23]  R. Henriksson,et al.  Spatial Expression of VEGF-A in Human Glioma , 2002, Journal of Neuro-Oncology.

[24]  J. Murray,et al.  Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy , 2002, British Journal of Cancer.

[25]  P. Black,et al.  Growth Factors in Glioma Angiogenesis: FGFs, PDGF, EGF, and TGFs , 2000, Journal of Neuro-Oncology.

[26]  K. Plate,et al.  Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible In vivo regulatory mechanisms , 1994, International journal of cancer.

[27]  Jonathan A. Sherratt,et al.  Models of epidermal wound healing , 1990, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[28]  S. Kramer,et al.  The extent of intracranial gliomata at autopsy and its relationship to techniques used in radiation therapy of brain tumors. , 1960, The American journal of roentgenology, radium therapy, and nuclear medicine.

[29]  T. Turpeenniemi‐Hujanen,et al.  Matrix Metalloproteinase 2 (MMP-2) Immunoreactive Protein is Associated with Poor Grade and Survival in Brain Neoplasms , 2004, Journal of Neuro-Oncology.

[30]  J. Murray,et al.  Quantifying Efficacy of Chemotherapy of Brain Tumors with Homogeneous and Heterogeneous Drug Delivery , 2002, Acta biotheoretica.

[31]  B. Sleeman,et al.  Mathematical modeling of capillary formation and development in tumor angiogenesis: Penetration into the stroma , 2001, Bulletin of mathematical biology.

[32]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[33]  S. Brem The role of vascular proliferation in the growth of brain tumors. , 1976, Clinical neurosurgery.